First- and second-generation drug-eluting balloons for femoro-popliteal arterial obstructions: Update of technique and results
The Journal of Cardiovascular Surgery: a journal on cardiac, vascular and thoracic surgery , Volume 54 - Issue 3 p. 327- 332
The use of drug-eluting balloons for treatment of long-segment femoropopliteal artery obstructions has become widespread in recent years. The possibility to deliver a drug into the arterial wall with sustained antiproliferative effects, without leaving behind metal scaffolding, seems very promising. The current generation of drug-eluting balloons differs in the formulation of the drug (usually paclitaxel), technique of coating, and the elution excipients. Results of published randomized trials are reviewed in this report. A new innovative coating technique has been introduced recently. The PRIMUS® coronary drug-eluting balloon and the Legflow® peripheral drug-eluting balloon consist of paclitaxel nanoparticles that are embedded underneath the surface of the balloon as well as inside a new shellolic acid drug-release matrix. Risk for dislodgement of the paclitaxel particles is minimized in the newest generation of drug-eluting balloons. Short-term in vitro and in vivo results of this stable, coated balloon are promising, and large randomized trials have been started recently to gather more longterm and robust clinical data.
|Angioplasty, Atherosclerosis, Paclitaxel, Peripheral artery disease|
|The Journal of Cardiovascular Surgery: a journal on cardiac, vascular and thoracic surgery|
de Vries, J.-P.P.M, Karimi, A, Fioole, B, van Leersum, M, Werson, D.A.B, & Van Den Heuvel, D.A.F. (2013). First- and second-generation drug-eluting balloons for femoro-popliteal arterial obstructions: Update of technique and results. The Journal of Cardiovascular Surgery: a journal on cardiac, vascular and thoracic surgery (Vol. 54, pp. 327–332). Retrieved from http://hdl.handle.net/1765/85572